Substandard and Falsified Medicines (WHO)


The presence of Substandard and Falsified (SF) medical products in countries, and their use by patients, impacts our ability to effectively tackle antimicrobial resistance (AMR). We need to investigate this use both to understand the true scale of AMR as well as how much SF medicines may be contributing to the growing resistance.

The Fleming Fund is supporting the World Health Organizations (WHOs) work on the prevention, detection and response to SF antibiotics in Africa and South and South East Asia. WHO’s work aims to decrease the risks of SF medical products contributing to AMR, particularly in low and middle-income countries (LMICs).

World Health Organization (WHO)

4 years (April 2018 - March 2022)

£4m

All countries will be supported to use the Global Surveillance and Monitoring System (GSMS). So far the following countries have been prioritised for the quality surveys: Sierra Leone, Ghana, Nigeria, Uganda, Burkina Faso, Tanzania, Malawi, Bangladesh.

Objectives

Activities

Other grants

The presence of Substandard and Falsified (SF) medical products in countries, and their use by patients, impacts our ability to effectively tackle antimicrobial resistance (AMR). We need to investigate this use both to understand the true scale of AMR as well as how much SF medicines may be contributing to the growing resistance.

Read more